All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Legend Biotech, Pfizer, Roche, and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
MagnetisMM-3: Impact of reduced elranatamab dosing frequency on PROs in RRMM
An analysis from the phase II MagnetisMM-3 trial (NCT04649359) evaluated the impact of lowering the frequency of elranatamab dosing from once a week (QW) to every 2 weeks (Q2W) on patient-reported outcomes (PROs) in 61 B-cell maturation antigen (BCMA)-naïve and 22 BCMA-exposed patients with relapsed/refractory multiple myeloma (RRMM). The results were published by Bahlis et al. in HemaSphere.
Key data: Switching to elranatamab Q2W dosing led to improvements in health-related quality of life (HRQoL), including fatigue, pain, disease symptoms, and overall quality of life (QoL), irrespective of prior exposure to BCMA therapies. These benefits were sustained up to 18 months. No worsening of symptoms or new safety signals were observed following the change in elranatamab dosing frequency.
Key learning: The findings support the feasibility of using reduced elranatamab dosing, highlighting the potential to improve patient outcomes in patients with RRMM, irrespective of prior exposure to BCMA-targeted therapies.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Which of the following reflects your thoughts about the feasibility of nursing staff preparing oncology treatments at the bedside at your clinical practice site, as opposed to in the pharmacy?
